Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. FDX
3. KBH
4. HON
5. HTZ
6. MRK
7. TTWO
8. USO
9. QCOM
10. INFY

Go back to Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1107.08 --0 (-0%)
Previous Close $1107.08    52 Week High $88.16 
Open $1107.08    52 Week Low $67.88 
Day High $1107.08    P/E 256.27 
Day Low $1107.08    EPS $4.32 
Volume 11,122